Tyrosine Kinase
- IGFBR(1)
- Bcr-Abl(65)
- Ack1(2)
- Axl(6)
- ALK(54)
- BMX Kinase(3)
- Broad Spectrum Protein Kinase Inhibitor(10)
- c-FMS(33)
- c-Kit(56)
- c-MET(81)
- c-RET(0)
- CSF-1R(3)
- DDR1/DDR2 Receptor(1)
- EGFR(229)
- EphB4(1)
- FAK(33)
- FGFR(87)
- FLT3(85)
- HER2(12)
- IGF1R(30)
- Insulin Receptor(41)
- IRAK(25)
- ITK(10)
- Lck(1)
- LRRK2(22)
- PDGFR(93)
- PTKs/RTKs(3)
- Pyk2(6)
- ROR(38)
- Spleen Tyrosine Kinase (Syk)(31)
- Src(90)
- Tie-2 (3)
- Trk(35)
- VEGFR(169)
- Kinase(0)
- Discoidin Domain Receptor(14)
- DYRK(26)
- Ephrin Receptor(12)
- ROS(14)
- RET(28)
- TAM Receptor(28)
Products for Tyrosine Kinase
- Cat.No. Product Name Information
-
GC67759
Lapatinib-d4
GW572016-d4; GW2016-d4
-
GC16021
Lavendustin A
NSC 678027, RG-14355
EGFR tyrosine kinase inhibitor -
GC19218
Lazertinib
YH25448
Lazertinib is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer. -
GC13117
Lck Inhibitor
Lymphocyte-specific Protein Tyrosine Kinase, RK-24466
A selective inhibitor of lymphocyte-specific protein tyrosine kinase - GC36430 Lck inhibitor 2 Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC50 values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively
- GC14241 LDC1267 TAM kinase inhibitor,highly selective
-
GC14552
LDK378
LDK 378;LDK-378;Ceritinib
LDK378 (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. - GC17452 LDK378 dihydrochloride
-
GC50327
LDN 193189 dihydrochloride
DM-3189
Potent and selective ALK2 and ALK3 inhibitor; promotes neural induction of hPSCs - GC33086 LDN-192960 LDN-192960 is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC50s of 10 nM and 48 nM, respectively.
- GC44047 LDN-192960 (hydrochloride) LDN-192960 is an inhibitor of haspin protein kinase and dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) with IC50 values of 10 and 48 nM, respectively.
- GC38403 LDN-192960 hydrochloride LDN-192960 hydrochloride is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC50s of 10 nM and 48 nM, respectively.
-
GC16580
LDN-193189
LDN 193189;LDN193189
ALK inhibitor,potent and selective - GC16798 LDN-211904 LDN-211904 (compound 32) is a potent and selective EphB3 inhibitor with an IC50 of 0.079 μM. LDN-211904 shows good metabolic stability in mouse liver microsomes. LDN-211904 with cetuximab could be effective in inhibiting STAT3-activated CSC stemness and cetuximab resistance in CRC.
- GC17035 LDN-212854 BMP receptor inhibitor,potent and selective
- GC13225 LDN-214117 potent and selective ALK2 inhibitor
-
GC14931
LDN193189 Hydrochloride
LDN 193189 hydrochloride; LDN-193189 hydrochloride
An inhibitor of BMP receptors ALK1, ALK2, ALK3, and ALK6 -
GC15454
Lenvatinib (E7080)
E-7080, ER-203492-00
Lenvatinib (E7080) (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities. -
GC36438
Lenvatinib mesylate
E-7080
An inhibitor of VEGFR2 and VEGFR3 -
GC17033
Lestaurtinib
CEP-701; KT-5555
A potent JAK2 and PRK1 kinase inhibitor -
GC17958
Linifanib (ABT-869)
Linifanib
Linifanib (ABT-869) (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (ABT-869) shows prominent antitumor activity. Linifanib (ABT-869) has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib (ABT-869) is a specific miR-10b inhibitor that blocks miR-10b biogenesis. -
GC15749
Linsitinib
OSI 906; OSI-906; OSI906
IGF1R/IR inhibitor,potent and novel - GC47570 Lipoxygenin An inhibitor of 5-LO
- GC17835 LM 22A4 tropomyosin-related kinase B (TrkB) agonist
- GC30770 LM22B-10 An activator of TrkB and TrkC
-
GC36425
LOXO-101 (Larotrectinib)
ARRY-470, Larotrectinib
LOXO-101 (Larotrectinib) (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C). - GC15282 LOXO-101 (Larotrectinib) sulfate LOXO-101 (Larotrectinib) sulfate (LOXO-101 sulfate; ARRY-470 sulfate) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).
-
GC19547
LOXO-292
selpercatinib
LOXO-292 (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. LOXO-292 has anticancer activity. - GC65390 LRRK2 inhibitor 1 LRRK2 inhibitor 1 is a potent, selective and oral LRRK2 inhibitor with an pIC50 of 6.8.
-
GC10809
LRRK2-IN-1
Leucine-rich repeat kinase 2 IN-1
A selective LRRK2 inhibitor -
GC69410
Lumretuzumab
Anti-Human ERBB3 Recombinant Antibody
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized monoclonal antibody that targets HER3 (ERBB3) and can be used for cancer research.
-
GC13848
LY2784544
Gandotinib
Potent inhibitor of JAK2 -
GC11057
LY2801653
Merestinib
A MET kinase inhibitor -
GC13424
LY2874455
LY 2874455; LY-2874455
A pan-FGFR inhibitor - GC40865 LYG-202 LYG-202 is a synthetic flavonoid with anticancer and anti-angiogenic activities.
- GC62314 M4205 M4205 is a c-KIT inhibitor, with an IC50 of 10 nM for c-KIT V654A. M4205 has high activity on c-KIT mutations in exon 11, 13, 17.
- GC68304 Margetuximab
- GC36546 Masitinib mesylate Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity.
-
GC66349
Mavrilimumab
CAM 3001
Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death. - GC65179 MAX-40279 MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase.
- GC64583 MAX-40279 hemiadipate MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase.
- GC64582 MAX-40279 hemifumarate MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase.
- GC16483 MAZ51 VEGFR3 antagonist
- GC64710 MC-Val-Cit-PAB-Amide-TLR7 agonist 4 MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a HER2-TLR7 and HER2-TLR8 immune agonist conjugate.
-
GC14951
Meleagrin
6-O-Methyloxaline
antibiotic - GC36585 Merestinib dihydrochloride Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib dihydrochloride also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM).
- GC68018 MET kinase-IN-2
-
GC12069
Methyl 2,5-dihydroxycinnamate
Methyl 2,5dihydoxycinnamate
EGF receptor-associated tyrosine kinases inhibitor -
GC36596
Methylnissolin
(–)-Methylnissolin
Methylnissolin (Astrapterocarpan), isolated from Astragalus membranaceus, inhibits platelet-derived growth factor (PDGF)-BB-induced cell proliferation with an IC50 of 10 μM. - GC13598 MGCD-265 MGCD-265 is a potent and oral active inhibitor of c-Met and VEGFR2 tyrosine kinases, with IC50s of 29 nM and 10 nM, respectively. MGCD-265 has significant antitumor activity.
- GC61516 MID-1 MID-1 is a disruptor of MG53-IRS-1 (Mitsugumin 53-insulin receptor substrate-1) interaction.
-
GC32819
Mirk-IN-1 (Dyrk1B/A-IN-1)
Dyrk1B/A-IN-1
Mirk-IN-1 (Dyrk1B/A-IN-1) is a potent inhibitor of Dyrk1B(Mirk kianse) and Dyrk1A with IC50 of 68±48 nM and 22±8 nM respectively. - GC16337 MK-2461 C-Met (WT/mutants) inhibitor
-
GC13140
MK-8033
MK 8033;MK8033
- GC36625 MK-8033 hydrochloride MK-8033 hydrochloride is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 hydrochloride can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs).
- GC47687 ML-209 An RORγt antagonist
-
GC17582
ML347
LDN193719
BMP receptor inhibitor,potent and selective - GC30769 MLi-2 An LRRK2 inhibitor
-
GC10775
MLR 1023
CP 26,154, NSC 314335
MLR 1023 is a potent and selective allosteric activator of Lyn kinase with an EC50 of 63 nM. -
GC10048
MNS
3,4Methylenedioxyβnitrostyrene, NSC 10120, NSC 105303, NSC 170724, Syk Inhibitor III
Inhibitor of Src/Syk tyrosine kinases -
GC47697
Mobocertinib
AP32788, TAK-788
An inhibitor of mutant EGFR and HER2 receptors - GC62160 Mobocertinib succinate Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research.
- GC13012 Motesanib
-
GC11336
Motesanib Diphosphate (AMG-706)
Motesanib
Motesanib Diphosphate (AMG-706) (AMG 706 Diphosphate) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret. -
GC69496
MRL-871
MRL-871 (compound 3) is an effective inverse agonist of retinoic acid receptor-related orphan receptor gamma t (RORγt), with an IC50 of 264 nM. MRL-871 has a unique imidazole chemical structure and can effectively reduce the generation of IL-17a mRNA in EL4 cells.
- GC13525 MRS 4062 triethylammonium salt P2Y4 receptor agonist
-
GC32769
MRX-2843 (UNC2371)
UNC2371
MRX-2843 (UNC2371) (UNC2371) is an orally active, ATP-competitive dual MERTK and FLT3 tyrosine kinases inhibitor (TKI) with enzymatic IC50s of 1.3 nM for MERTK and 0.64 nM for FLT3, respectively. - GC65243 MS4077 MS4077 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a Kd of 37?nM for binding affinity to ALK.
- GC64966 MS4078 MS4078 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a Kd of 19?nM for binding affinity to ALK.
-
GC15936
MSDC-0160
Mitoglitazone; CAY10415
mTOT-modulating insulin sensitizer -
GC64431
MSDC-0602K
Azemiglitazone potassium
MSDC-0602K (Azemiglitazone potassium), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC50 of 18.25 μM. -
GC19256
MTX-211
Mol 211
MTX-211 is a dual inhibitor of EGFR and PI3K, used for the treatment of cancer and other diseases. -
GC10250
Mubritinib (TAK 165)
TAK-165
Mubritinib (TAK 165) (TAK-165) is a potent and selective EGFR2/HER2 inhibitor with an IC50 of 6 nM. - GC11126 Mutant EGFR inhibitor Selective Mutated EGFR inhibitor
- GC36666 Mutated EGFR-IN-1 Mutated EGFR-IN-1 (Osimertinib analog) is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant and T790M resistance mutant.
- GC36667 Mutated EGFR-IN-2 Mutated EGFR-IN-2 (compound 91) is a mutant-selective EGFR inhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC50=<1nM) and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. Mutated EGFR-IN-2 shows anti-tumor antivity.
-
GC44263
Myrtillin
Delphinidin-3-β-D-glucoside chloride, Delphinidin-3-O-glucoside, Delphinin
Myrtillin (Delphinidin 3-O-glucoside chloride) is an active anthocyanin found in bilberry extract. Myrtillin induces a pro-apoptotic effect in B cell chronic lymphocytic leukaemia (B CLL). Myrtillin exerts phytoestrogen activity by binding to ERβ, with an IC50 of 9.7 μM. Delphinidin-3-O-glucoside chloride inhibits EGFR with an IC50 of 2.37 μM. -
GC40567
N-(p-Coumaroyl) Serotonin
NSC 369503
N-(p-Coumaroyl) serotonin is an antioxidative phenolic naturally found in plants, including safflower seed and millet grain. - GC11526 N-Acetyl-O-phosphono-Tyr-Glu Dipentylamide Phosphopeptide for binding to the src SH2 domain
- GC12746 N-Acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu Phosphopeptide ligand for the src SH2 domain
-
GC15365
N-Acetylserotonin
N-Acetyl-5-hydroxytryptamine,NAS
N-Acetylserotonin is a Melatonin precursor, and that it can potently activate TrkB receptor. - GC49686 N-desmethyl Regorafenib N-oxide An active metabolite of regorafenib
-
GC44290
NAADP (sodium salt)
Nicotinic acid adenine dinucleotide phosphate
Nicotinic acid adenine dinucleotide phosphate (NAADP) is a secondary messenger that induces calcium mobilization.
- GC33045 NAMI-A NAMI-A is a ruthenium-based drug characterised by the selective activity against tumour metastases, inhibits the adhesion and migration.
-
GC33022
Naquotinib (ASP8273)
ASP8273
Naquotinib (ASP8273) (ASP8273) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR. -
GC32836
Naquotinib mesylate (ASP8273)
ASP8273 (mesylate)
Naquotinib mesylate (ASP8273) (ASP8273 mesylate) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR. -
GC36699
Nazartinib mesylate
EGF816 mesylate
Nazartinib mesylate (EGF816 mesylate) is a novel, covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min?1 on EGFR(L858R/790M) mutant, respectively. - GC40623 NBI 31772 NBI 31772 is a nonpeptide ligand that releases insulin-like growth factor-1 (IGF-1) from its binding protein (IGFBP; Kis = 1-24 nM for the six human subtypes of IGFBP).
- GC61111 NBI-31772 hydrate NBI-31772 hydrate is a potent inhibitor of interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs).
-
GC10644
Neoruscogenin
25(27)-Dehydroruscogenin
nuclear receptor RORα agonist -
GC10362
Neratinib (HKI-272)
HKI-272;HKI272;HKI 272
Neratinib (HKI-272) (HKI-272) is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC50s of 59 nM and 92 nM, respectively. - GC47771 NG 25 (hydrochloride hydrate) An inhibitor of MAP4K2 and TAK1
- GC60270 Nilotinib D6 An internal standard for the quantification of nilotinib
-
GC25669
Nilotinib hydrochloride
AMN-107 HCl
Nilotinib hydrochloride (AMN-107) is the hydrochloride salt form of nilotinib, an orally bioavailable Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. - GC14237 Nilotinib monohydrochloride monohydrate A Bcr-Abl inhibitor
-
GC14129
Nilotinib(AMN-107)
AMN107
A Bcr-Abl inhibitor - GC62601 Nimotuzumab Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor drug, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC).
- GC18211 Ningetinib A multi-kinase inhibitor
- GC36744 Ningetinib Tosylate Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.
-
GC11705
Nintedanib (BIBF 1120)
Vargatef
A VEGFR, FGFR, and PDGFR inhibitor